Expedeon AG (FSE: EXNN, ISIN: DE000A2Y801, Prime Standard)

Expedeon is an enabler of exciting advances in medical science and patient care. The Company’s core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon’s technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers’ development and commercialisation objectives. Expedeon’s products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXNN; ISIN: DE000A2YN801). *

	Start	2019-11-11 existent
	End	2020-01-01 renamed
	Group	2invest (Group)
	Industry	BIOTECH

	Region	Heidelberg
	Country	Germany
	City	n. a. Heidelberg
		Address record changed: 2019-11-20

Basic data	Employees	n. a.

		* Document for »About Section«: Expedeon AG. (11/11/19). "Press Release: Expedeon AG Signs EUR 120 Million Deal with Abcam for the Sale of Its immunology and Proteomics Business". Heidelberg & Cambridge.

		Record changed: 2025-03-16